Evaluation of the efficacy and safety of topical application of polyherbal unani formulation in the management of Melasma
- Conditions
- Health Condition 1: L80-L99- Other disorders of the skin and subcutaneous tissue
- Registration Number
- CTRI/2024/02/063053
- Lead Sponsor
- Hakim Syed Ziaul Hasan Government Unani Medical College and Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1 Clinically diagnosed patients of Kalf (Melasma) by wood’s lamp examination.
2 Patients with Fitzpatrick skin types III, IV and V
3 Patients of all sexes.
4 Patients who are willing to sign the written consent form prior to participation in the study.
1 Pregnant and lactating women.
2 Patients having used any cosmetic depigmenting agent within 2 weeks prior to inclusion in the study.
3 Female on oral contraceptives and hormone therapy at the time of study.
4 Patients having used topical or systemic corticosteroid within 1 month prior to inclusion in the study.
5 Patients having history of laser treatment or dermabrasion or deep facial peels within the past 3 months.
6 Patients who have a known history or clinically relevant allergy, to any study medication components.
7 Patients who have a known history of renal insufficiency, severe liver or heart diseases, neurological disorders, malignancy, HIV infection, AIDS, etc.
8 Patients unlikely to comply with the study protocol.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method • modified Melasma Area Severity Index (mMASI) <br/ ><br>• Patient Global <br/ ><br>Assessment (PtGA)Timepoint: Baseline,2nd week, 4th week and 6th week
- Secondary Outcome Measures
Name Time Method Melasma quality of life scale (MELASQoL)Timepoint: Baseline and 6th week